Abstract apo E has been shown to modulate cholesterol balance in arterial wall cells. Production of apo E by macrophages in atherosclerotic plaques could thereby influence the development of the plaque lesion. Cytokines, including TNFa, have been identified in human lesions, therefore, we undertook a series of studies to evaluate the effect of TNFa on monocyte/ macrophage apo E production. The addition of TNFa to freshly isolated human monocytes led to a four-to fivefold increase of apo E mRNA abundance. The addition of TNFa to fully differentiated macrophages either had no effect or modestly inhibited apo E mRNA expression. THP1 human monocytic cells also responded to TNFa in a phenotypespecific manner. Treatment of these cells with TNFx produced a dose-and time-dependent increase in apo E mRNA. This increase was reflected in apo E synthesis and was associated with inhibition of DNA synthesis, and with induction of c-fos and ICAM-1 gene expression. Cell-permanent analogues of ceramide did not reproduce TNFa effect on apo E, but antagonists of protein kinase C did inhibit its effect. TNFa induction of apo E mRNA abundance was associated with stimulation of apo E promoter-dependent gene transcription. In summary, TNFa stimulates apo E gene transcription, mRNA abundance, and protein synthesis in the monocyte/macrophage in a phenotype-specific manner.
Introduction apo E is an important structural and functional constituent of plasma lipoproteins, including VLDL, HDL, and chylomicron remnants (1) . Although apo E is primarily synthesized by the liver, significant amounts are also produced by a variety of peripheral tissues and cells (2) , including macrophages, where its synthesis is regulated by the cholesterol content of the cells (3, 4) . Histochemical studies have indicated that macrophages are the major source of locally derived apo E in developing vessel wall atheromatous lesions (5) . Local production of apoE in the vessel wall could impact on proximate cellular cholesterol flux and modify the local availability of bioactive molecules such as growth factors (1) . Furthermore, endogenous production of apo E has been shown to influence macrophage cholesterol flux by regulating the rate of cellular cholesterol clearance to HDL3 (6) . Thus, modulation of macrophage apo E secretion in the vessel wall could significantly impact atheroma progression or regression.
Regulation of macrophage apo E expression is complex: it is regulated not only by cholesterol but also by activators of protein kinase C and by endotoxin (7) (8) (9) . TGF, 8 has been demonstrated to induce macrophage apo E expression (10) . On the other hand, the monocyte colony stimulating factor (MSCF)' has been shown, in separate reports, both to inhibit and augment macrophage apo E expression ( 10, 11) . A potential regulatory role for other cytokines, for example, TNFa, has been even less clear (10, 12) .
Local production of TNFa is an important component of the vessel wall response to injury. TNFa positivity has been found in the cytoplasm of macrophages, and in the cytoplasm and attached to cell membranes of smooth muscle cells and endothelial cells of the human atheroma ( 13, 14) . These observations suggest a potential for TNFa to modulate the evolution of the atherosclerotic plaque. Further, such modulation would be likely to occur via effects on monocyte/macrophage cells because these are primary targets of TNFa action. In the present study, we investigated the effect of TNFa on apoE expression in the human monocyte/macrophage. We examined phenotypedependent effects of TNFa on apo E gene expression and compared these with its effects on the expression of other monocyte/ macrophage genes (c-fos and intercellular adhesion molecule [ICAM] -1 ) and cell cycle traverse. We also investigated potential roles for ceramide second messengers and protein kinase C (pkC) activation for transducing the observed effects of TNFa on apo E. (6, 9, 15, 16) .
Methods
Cell culture. Freshly isolated human monocytes were purified by elutriation. The cell population used for experiments was > 95% monocytic, as determined by differential counts of Wright stained smears. These cells were incubated using conditions described in the figure legends. For experiments using fully differentiated human monocytederived macrophages, cells were allowed to differentiate in serum-containing medium for 7 d before the start of the incubation with TNFa. The THPl human monocytic cell line was obtained from American Type Culture Collection (ATCC, Rockville, MD), and cells were grown in culture flasks (Falcon Plastics, Cockeysville, MD) in RPMI-1640 medium containing 10% heat-inactivated FBS as described (15) . For experiments, all cells were washed twice with serum-free RPMI-1640 and were placed in RPMI-1640 medium supplemented with 0.2% endotoxin-free BSA unless otherwise indicated.
Immunoprecipitation of apo E. THP1 cells were pulse-labeled with L-[35S ] methionine, as described in detail previously (16) . Briefly, cells were plated at a density of 5 x 106 cells in a 60-mm dish in triplicate. 5 ng/ml of TNFa was added, and the cells were incubated for 72 h at 37TC. After incubation, adherent cells and cells in suspension were washed twice with methionine-free RPMI-1640 and then incubated for 2 h in 1 ml of methionine-free RPMI-1640 medium supplemented with 100 ,uCi/ml of [35S]methionine supplemented with 10 uM unlabeled L-methionine. After incubation, the medium was collected after centrifugation to remove cells. Adherent and cells in suspension were washed twice in ice-cold phosphate-buffered saline and lysed in 2.0% SDS at 950C for 3 min. The lysate was then diluted with lysis buffer (10 mM Na2HPO4, 15 mM NaCl, 10 mM L-methionine, 1% Triton X-100, 1% deoxycholate, pH 7.4) to final concentration of 0.2% SDS. Cell extracts and culture media were analyzed by immunoprecipitation followed by 10% SDS-PAGE and fluorography as previously described (16) . 4 x 106 TCA-precipitable counts/min were immunoprecipitated from each cell lysate sample, and 4 x 105 counts/min were immunoprecipitated from each medium sample. Incorporation of labeled methionine into apo E protein in THP1 cells was linear over the assay period. For quantitation, apo E bands were excised from the gel and digested in 30% H202 for scintillation counting (16) . Radioactivity in the apo E shown was normalized for rate of total protein synthesis and secretion, which was not significantly different between groups.
RNA isolation and Northern hybridization. Cells were seeded at a density of 10 x 106 cells in a 100-mm dish. To isolate total cellular RNA, washed cells were solubilized in guanidine isothiocyanate as described, followed by sedimentation of the extract through CsCl (9) . For some experiments, poly (A)+ RNA was purified after passing total RNA through silanized oligo (dT) columns. For Northern analysis, formaldehyde-treated RNA samples were fractionated by electrophoresis in 1.0% agarose, transferred to Nytran (Schleicher & Schuell, Inc., Keene, NH), and hybridized with a labeled apo E cDNA probe as previously described (9) . Radiolabeled apo E cDNA probe was prepared by random-primed synthesis using pHEA4, which is a 1.1-kb AatllHinf I fragment that encompasses the entire protein coding region of the human apo E cDNA subcloned into pUC (9) . Each reaction was carried out using 50 ng of cDNA with a minimum of 1 x 107 cpm. To provide an internal control, Nytran membranes were stripped according to the manufacturer's instructions and reprobed with a labeled 0.7-kb PstI fragment of the cDNA for beta-actin. The c-fos probe, which was a 1.0-kb PstI subfragment from thef os cDNA and the ICAM-1 probe, which was a 1.4-kb BgIII-SaII subfragment from the ICAM-1 cDNA, was labeled using the same method.
Measurement apo E/beta-actin with 100 ng/ml of PMA alone or with 5 ng/ml of TNFa for 18 h.
Northern blots of poly (A) + RNA for apo E and /3-actin were processed as described in Methods. The bars show the change of apo E mRNA abundance after correcting for the /3-actin signal. (24) (25) (26) . These effects can be reproduced by treating cells with cell permeable analogues of ceramide, and we used this approach to evaluate the importance of this second messenger for transducing the effect of TNFa on apo E gene expression. As shown in Fig. 3 (upper panel) , C2-ceramide did not reproduce the effect of TNFa on apo E gene expression, nor did it potentiate the effect of TNFa on this gene. Similarly, C2-ceramide did not reproduce the effect of TNFa on ICAM-1 expression. In this case, however, the TNFa effect was potentiated by ceramide (Fig. 3, middle panel) . Neither extending the incubation in C2-ceramide for up to 72 h, addition of C6-ceramide analogues, nor treatment of cells with (24) (25) (26) . We therefore examined whether pathway inhibition of pkC activation during TNFa treatment would attentuate apo E gene response. In the experiment shQwn in the bottom panel of Fig. 3 , treatment with TNFa produced a significant increase in apo E gene expression (P < 0.02). Concurrent treatment with the pkC inhibitor H7, 1-(5-isoquinolinesulfonyl)-2-methylpiperazine, completely prevented this induction however. A similar inhibition of TNFa stimulation was produced by using staursporine to inhibit pkC activity (not shown).
Effect of TNFa on apo E gene transcription. We next considered the mechanism by which TNFa increases apo E mRNA abundance. For other macrophage genes, TNFa has been shown to increase mRNA abundance by stabilization of mRNA species without any change in gene transcription rate. To assess the contribution of increased apo E gene transcription, THP1 cells were transiently transfected with a chimeric construct containing apo E promoter sequences (from -2300 to +24 bp) fused to a luciferase reporter. After transfection, a single pool of cells was created to normalize transfection efficiency, and this pool was then aliquoted for incubations in TNFa treatment for 24 and 48 h. TNFa induced the expression of this chimeric construct 2.2-fold at 24 h and 2.1-fold at 48 h (Fig. 4) .
Discussion
Our studies demonstrate that treatment with TNFa stimulates apo E gene transcription, mRNA abundance, and apo E synthesis and secretion in monocyte/macrophage cells in a phenotypedependent manner. Such concordant response at all major regulatory loci is not demonstrated by all macrophage targets of TNFa modulation. For example, for FCy HIb, TNFa has been shown to decrease protein expression but increase mRNA abun- dance in macrophages, and this increased mRNA abundance is due to a change in mRNA stability (21). While our studies establish that increased apo E gene transcription contributes to enhanced apo E mRNA abundance after TNFa treatment, a (22, 27) . Such a phenotype-dependent response to cytokine stimulation may be related to activation of endogenous cytokine synthesis and secretion by the fully differentiated and activated macrophage. For example, PMA stimulation has been shown to increase TNFa mRNA expression within 3 h and TNFa protein synthesis within 10 h in human monocytes (28) . However, if endogenous synthesis of TNFa by differentiated macrophages accounts for the lack of apo E induction after treatment with exogenous TNFa, the suppression of apo E expression observed by Zuckerman et al. (10) and by us (Table I) during prolonged incubations in TNFa would not be expected. Alternatively, phenotype-specific effects of TNFa may relate to differences in cell-matrix interactions between monocyte and macrophage phenotypes. Adhesion of cells to extracellular matrix has been shown to modify their response to TNFa (29) . Further, in the vessel wall, it is likely that the presence of other cytokines will be involved in modulating monocyte/macrophage response to TNFa. Interferon-y, for example, has been shown to be an important influence on the response of the IGF-1 expression after treatment of macrophages with TNFa (30) .
TNFa treatment produced cell cycle arrest as indicated by (35) ; however, in our laboratory, the addition of MCSF, with or without phorbol ester, to THP1 cells also had no effect on apo E mRNA abundance. This agrees with the report of Brand et al., who made a similar observation regarding the lack of MCSF effect on apo E protein synthesis and secretion in these cells (34) . Treating cells with TNFa has reportedly produced sphingomyelin turnover as well as endogenous cellular ceramide (24) (25) (26) . Investigation of biologically important signal transduction pathways for TNFa has focused on the role of ceramide as a second messenger as well as on a potential role for pkC activation. There are examples of pkC activation and ceramide producing opposing effects in target monocyte/macrophage cells (26) . In HL60 cells, TNFa leads to increased activity of mitogen-activated protein kinase and the accumulation of nuclease factor-kB (NFkB) (36, 37) . Both of these effects can be reproduced by exogenously added ceramide analogues. In Jurkat cells, TNFa decreases DNA synthesis and increases NFkB accumulation (38) . In these cells, ceramide inhibits DNA synthesis but does not produce NFkB accumulation, although it potentiates the effect of TNFa on NFkB accumulation. These observations support a role for ceramide as a second messenger molecule mediating TNFa effects. Recently, however, the importance of ceramide as a TNFa second messenger has been questioned. For (40, 41) . TNFa produced in the vessel wall could significantly modulate the abundance of apo E derived from monocytes/macrophages that are newly recruited into the vessel wall and thereby influence the genesis of the vessel wall lesion.
